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Glycosylceramides in mammalian species are
thought to be present in the form of b-anomers.
This conclusion was reinforced by the identification
of only one glucosylceramide and one galactosylcer-
amide synthase, both b-transferases, in mammalian
genomes. Thus, the possibility that small amounts
of a-anomers could be produced by an alternative
enzymatic pathway, by an unfaithful enzyme, or
spontaneously in unusual cellular compartments
has not been examined in detail. We approached
the question by taking advantage of the exquisite
specificity of T and B lymphocytes and combined it
with the specificity of catabolic enzymes of the
sphingolipid pathway. Here, we demonstrate that
mammalian immune cells produce constitutively
very small quantities of a-glycosylceramides, which
are the major endogenous ligands of natural killer
T cells. Catabolic enzymes of the ceramide and
glycolipid pathway tightly control the amount of
these a-glycosylceramides. The exploitation of this
pathway to manipulate the immune response will
create new therapeutic opportunities.
INTRODUCTION
The biosynthetic pathways of glycolipids were described many
decades ago in the context of enzymatic deficiencies that lead
to inherited human diseases of the nervous system (Schulze
and Sandhoff, 2011; Wennekes et al., 2009). A very good map
of enzymes, their substrates, and their products was produced
by classical biochemical methods and has not been challenged
since. However, all lipid analytical methods lack sensitivity; it is
nearly impossible to detect contaminations below 0.5%–1% in
natural or synthetic preparations of lipids and glycolipids (Meisen
et al., 2011). On the contrary, biological assays are exquisitelysensitive to low amounts of otherwise unmeasurable molecules.
This particular situation has hampered the identification of immu-
nologically relevant lipid species, a family of antigens that are pre-
sented toTcells by the family ofmajor histocompatibility complex
(MHC)-like molecules called CD1 (Bendelac et al., 2007).
In the current work, we have combined biological assays with
immunological and enzymatic assays to interrogate glycolipid
populations in order to elucidate the identity of glycolipids
capable of triggering the activation of a regulatory T cell subset
called type 1 natural killer T (NKT) cells; NKT cells make up a
small population that sits at the interface between innate and
adaptive immunities and is critical for the coordination of T and
B cell responses (Bendelac et al., 2007). NKT cells are recruited
very rapidly and transiently in the context of all microbial aggres-
sions to allow the maturation of dendritic cells (DCs) and the
recruitment of immune cells at the site of injury (Bendelac
et al., 2007). The activation of NKT cells is believed inmany cases
to be dependent on the display of endogenous glycolipids by
DCs in the context of CD1 MHC-like molecules. NKT cells are
capable of almost immediate responses, leading to the hypoth-
esis that endogenous ligands are either premade or quickly pro-
duced by an enzymatic modification that is tightly controlled to
avoid persistent or overt activation leading to activation-induced
cell death or stunning, such as when strong agonists are used
(Wilson et al., 2003). A large number of potential self-antigens
have been proposed over the years, and all are capable of acti-
vating NKT cells in vitro and/or in vivo (Brennan et al., 2011; Fac-
ciotti et al., 2012; Zhou et al., 2004b). It has proven difficult to
study the chemistry of these potential candidates because of
low sensitivity of the assays. To overcome the limitations of
direct chemical methods, we have used the specificity of immu-
nological and enzymatic assays to characterize and isolate the
endogenous ligands of NKT cells in the thymus and in DCs.
We found that these stimulatory NKT agonists are a-linked
monoglycosylceramides, a class of glycolipids that were thought
to be absent frommammalian cells given that the only two glyco-
sylceramide synthases (glucosylceramide synthase [GCS] and
ceramide galactosyltransferase [CGT]) were thought to be in-
verting glycosyltransferases; through a SN2-like ligation, these
enzymes transfer a-glucose and a-galactose from uridineImmunity 41, 543–554, October 16, 2014 ª2014 Elsevier Inc. 543
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Figure 1. b-GluCer Is Not the Endogenous Ligand of NKT Cells
(A) Comparison of the stimulatory capacity of commercial (closed circles) and in-house (open circles) C24:1 b-GluCer presented by DCs to DN32.D3 NKT cells.
(B) CD1d tetramers loaded with control lipid, C24:1 b-GluCer, or C24:1 a-GalCer were used to stain DN32.D3 NKT hybridoma cells and splenocytes and were
examined by flow cytometry.
(C) b-GluCer was digested with recombinant GBA for 2 hr at 37C, analyzed by TLC for confirmation of complete digestion (left panel), and tested functionally for
its ability to stimulate DN32.D3 NKT cells when presented by WT splenocytes before (squares) and after (circles) digestion (right panel).
(D) The stimulatory activity of commercial b-GluCer was blocked by L363 (10 mg/ml; diamonds) and 20H2 (5 mg/ml; triangles), but not control (squares) antibodies
(left panel), and could be recoveredwith Pisum sativum lectin (right panel), an agglutinin specific to a-glucose (closed squares). Unbound fractions were used as a
negative control (open circles). Seven two-fold dilutions of the purified material were used.
All experiments were repeated a minimum of three times with similar results. See also Figure S1.
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Endogenous a-Linked Ceramides Control NKT Cellsdiphosphate (UDP)-sugar moieties in a b-anomeric linkage on a
ceramide (Lairson et al., 2008). In addition, we demonstrate that
catabolic enzymes tightly control the level of a-galactosylcera-
mide (a-GalCer) in cells and tissues.
RESULTS
b-Glucosylceramides Are Not the Natural Endogenous
Ligands of NKT Cells
It has recently been proposed that b-linked monoglycosylcera-
mides, such as b-glucosylceramides (b-GluCer), were natural
endogenous ligands of NKT cells, and synthetic preparations of
C12:0 and C24:1 b-GluCer have been shown to be strong activa-
tors of type 1 NKT cells (Brennan et al., 2011; Ortaldo et al., 2004;
Parekh et al., 2004; Zigmond et al., 2007). However, because of
the limitations of the analytical methods of lipids, the possibility
that a-anomers could contaminate the synthetic preparations544 Immunity 41, 543–554, October 16, 2014 ª2014 Elsevier Inc.could not be easily ruled out. In addition, because b-GluCer is
one of the most abundant glycosylceramides in all cell types, it
remains verydifficult to conceive the regulation of its presentation
byCD1molecules and recognition byNKT cells.We repurified by
normal-phase chromatography a large quantity of commercial
C24:1 b-GluCer and isolated seven fractions. Each was tested
for the presence of b-GluCer by immunoblot using a polyclonal
rabbit serum against b-GluCer, and only one fraction, fraction
3, tested positive (Figure S1, available online). However, in func-
tional assays, six of the seven fractions were stimulatory.
We synthesized C24:1 b-GluCer and tested it for presentation
byDCs to the prototypic NKT cell hybridomaDN32.D3 and found
no stimulation of DN32.D3 cells for this synthetic product, even
at a high concentration (Figure 1A). We routinely used this test
to assess the lack of a-anomer contamination in our b-anomer
synthesis. The suspicion of contamination was confirmed by
three experiments. First, we loaded CD1d-GT1b tetramers with
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Figure 2. The Anti-CD1d-a-GalCer Antibody
L363 Blocks the Autoreactivity of CD1-
Expressing Cells toward NKT Cells
(A) IL-2 production by Va14-expressing DN32.D3
NKT cells was tested after a 24 hr exposure to
increasing numbers of RBL-CD1d cells in the
presence of L363 (red dots) or control (black dots)
antibody (10 mg/ml; left panel).
(B) Tested under similar conditions, the non-Va14
NKT cell hybridoma, TBA7, was not affected by
antibody treatment.
(C) The stimulatory activity of WT thymocytes to-
ward DN32.D3 cells was tested in the presence of
control (black dots) or L363 (red dots) antibody
(20 mg/ml).
(D) A total of 2 3 104 DC3.2 cells treated for 16 hr
with increasing concentrations of LPS were used
to stimulate DN32.D3 cells in the presence of
control (black dots) or L363 (red dots) antibody
(10 mg/ml).
(E and F) Stimulation of DN32.D3 cells (E) and
TBA7 cells (F) was tested against RBL-CD1d cells
(black dots) or RBL-CD1d saposin-knockdown
cells, in which saposin expression was reduced to
undetectable levels with interfering RNAs. IL-2
productionwasmeasuredwith the NK reporter cell
line from triplicate wells.
Experiments shown are representative of at least
five independent experiments. See also Figure S2.
Immunity
Endogenous a-Linked Ceramides Control NKT Cellscommercial and in-house C24:1 b-GluCer in the presence of
saposin B at acidic pH to allow exchange and completion of lipid
loading. We used the C24:1-b-GluCer-CD1-loaded tetramers
to stain DN32.D3 cells and polyclonal NKT populations from
C57BL/6 mice and used C24:1-a-GalCer-loaded tetramers as
positive controls. No staining of NKT cells could be observed,
even at very high concentrations of tetramer (Figure 1B). Second,
we produced recombinant acid glucosylceramidase (GBA), an
enzyme specific to b-GluCer (Kacher et al., 2008), in fly cells
and used it to digest fraction 3 to completion to produce glucose
and ceramide (Figure 1C). This enzymatic treatment did not
affect the stimulatory activity of the commercial C24:1 b-GluCer
(Figure 1C), ruling out that b-GluCer could be an agonist of NKT
cells. Finally, we confirmed the presence of a-linked contami-
nants by blocking the stimulatory activity with the anti-CD1-
a-GalCer antibody L363 and by purifying stimulatory com-
pounds with Pisum sativum agglutinin, an anti-a-linked glucose
lectin (Figure 1D and Figure S1). On the basis of the half maximal
inhibitory concentration (IC50) in T cell assays of pure a-linked
GluCer agonists, we could estimate that the contamination
of commercial C24:1 b-GluCer with a-species was in the order
of 0.2%–2%. Thus, concurrent evidence demonstrates that
b-GluCer has no stimulatory properties toward NKT cells
and that contamination of synthetic b-linked glycolipids with
a-anomers is an important issue for biological studies.
‘‘Autoreactivity’’ of NKT Cells toward Cellular Ligands
NKT cells have a memory phenotype and hallmarks of ‘‘pre-
activation’’ when analyzed ex vivo. In vitro, they have been
described as being highly autoreactive given their propensityfor being activated by syngeneic target cells expressing CD1d
molecules (Bendelac et al., 2007; Park et al., 1998). This phe-
nomenon is well illustrated by the activation of Va14 NKT hybrid-
oma cells, such as DN32.D3 cells, against CD1d-positive cell
lines (such as rat basophilic leukemia [RBL]-CD1d cells; Figures
2A and 2B), primary cells (such as thymocytes; Figure 2C), and
DCs that have been stimulated by Toll-like receptor (TLR) ligands
(Figure 2D). The presentation of endogenous ligands requires a
competent lysosome and lipid-transfer proteins (Zhou et al.,
2004a), as illustrated in Figures 2E and 2F by the large decrease
in stimulatory activity produced by the knockdown of prosaposin
in RBL-CD1d cells. In these assays, as expected, anti-CD1 anti-
bodies, such as 20H2, blocked the activation of DN32.D3 cells
(Roark et al., 1998).
To probe the structure of the stimulatory CD1-lipid complexes,
we used the antibodies L317 and L363. Both antibodies are
specific to the complex CD1d-a-GalCer (Yu et al., 2007). The
crystal structure of CD1d-a-GalCer in complex with L363 shows
how the antibody can see both CD1 and the a-linked sugar
(Yu et al., 2012). We used this structure to demonstrate by
modeling that L363 could not bind b-linked glycolipids or digly-
cosylceramides because of obvious steric hindrances and that
galactose was seen better than glucose as a result of a unique
hydrogen bond between the C4 hydroxyl group of the sugar
and the antibody (Figure 3A). As a control, we added L317
and L363 antibodies to the autoreactivity assays to determine
their impact on endogenous antigen presentation. As shown
for L363, both antibodies efficiently blocked the activation of
DN32.D3 cells by RBL-CD1d cells, thymocytes, and TLR-acti-
vated DCs (Figures 2A, 2C, and 2D, respectively), whereasImmunity 41, 543–554, October 16, 2014 ª2014 Elsevier Inc. 545
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Figure 3. The L363 Antibody Binds with
Different Affinity to Both CD1-a-GalCer
and CD1-a-GluCer Complexes but Does
Not Recognize b-Glycosylceramide-CD1d
Association
(A) Predicted L363 binding to glycosylceramides.
In the crystal structure, L363 contacts a-GalCer
with two H-bonds, G50 interacts with the axial 400-
OH, and R32 is specific to the sphingosine chain
(Protein Data Bank [PDB] ID 3UBX, left panel).
Modeling the interaction with a-GluCer illustrates
the loss of the H-bond with G50, which as a result
of equatorial rather than axial position of 400-OH,
leads to weaker L363 binding affinity (middle
panel). However, N31 and R32 together form a
cap over the sugar and bind through van der
Waals interactions, predominantly through N31.
The upright positioning of b-GalCer (modeled with
the crystal structure of mCD1d-sulfatide [PDB ID
2AKR]) would prevent L363 binding as a result of
steric clashes (right panel).
(B) The binding of the various a- and b-anomers of
glycosylceramides mentioned and depicted in
Table 1 was measured by SPR on a Biacore T200
instrument. Single-cycle analysis was performed
on CM5 chips with 500–1,000 response units of
immobilized antibody and increasing concentra-
tions of the various CD1-lipid complexes. Analysis
was performed with the Biacore T200 Biaevalua-
tion global analysis software with subtracted
sensorgrams (L363 antibody was used as a con-
trol antibody). Similar results were obtained in five
independent experiments.
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Endogenous a-Linked Ceramides Control NKT Cellsthey did not affect the activation of non-Va14 NKT cells, such as
TBA7 cells (Figure 2B). The observation was expanded to the
blocking of interferon-g (IFN-g) and interleukin-4 (IL-4) secretion
by a polyclonal NKT cell line stimulated by in-vitro-matured
bone-marrow-derived DCs (Figure S2). Because the specificity
of antibodies is so exquisite, these results strongly suggest
that the ligands for Va14 NKT cells are a-linked monoglycosyl-
ceramides. In addition, the L363 antibody was also unable to
block the stimulation of DN32.D3 T cells by DCs loaded with iso-
globotrihexosylceramide (iGb3), a known agonist of NKT cells
(Zhou et al., 2004b; data not shown).
The Endogenous Ligands of NKT Cells Are
Monoglycosylceramides
To unambiguously confirm these data, we examined the binding
of the L363 antibody by surface plasmon resonance (SPR)
against a large series of a- and b-GluCer and -GalCer. All
a-linked monoglycosyl species demonstrated measurable bind-546 Immunity 41, 543–554, October 16, 2014 ª2014 Elsevier Inc.ing and a strong preference for galactose
over glucose (Figure 3B and Table 1).
Binding of b-linked glycolipid-CD1 com-
plexes could not be detected for either
L317 or L363 antibody. Diglycosylcera-
mides, such as a-Gal(a1-2)galacto-
sylceramide, and trihexosylceramides,
such as iGb3, loaded into CD1d also ex-
hibited no ability to bind the same anti-bodies (data not shown). Interestingly, we also demonstrated
the binding of L363 and L317 to CD1 loaded with a-lyso-galac-
tosylceramide (a-psychosine) and a-lyso-glucosylceramide
(a-glucopsychosine), two compounds that are potent stimula-
tors of NKT cells in vitro and in vivo.
Because it is likely that the endogenous ligands are made in
very small amounts, we decided to isolate them from cell lines
that we could grow in large quantities. For enrichment and puri-
fication, we used L363 immunoprecipitation in the presence of
a detergent that was compatible with mass spectrometry (MS)
analysis and unlikely to compete with CD1-bound lipids
efficiently. Sodium 3-[(2-methyl-2-undecyl-1,3-dioxolan-4-yl)
methoxy]-1-propanesulfonate satisfied most of these criteria
and was shown in vitro to not bind CD1d to any measurable
extent. Because both L317 and L363 antibodies have low affinity
for their antigens and because these antigens are present at low
density on cell surfaces (no staining by flow cytometry), we
decided to use multiple reaction monitoring (MRM)-MS
Table 1. Affinity Constants of L363 for a Series of a- and b-Monoglycosylceramide Anomers Bound to CD1d
Lipid Name Affinity (Kdiss / Kass = Kd) s
1 / M.s1 = M Structure
a-GalCer 0.0083 / 8.57 3 104 = 9.67 3 108
C24:1 a-GalCer 0.05 / 1.42 3 105 = 3.50 3 107
C24:1 b-GalCer NM
a-psychosine 0.021 / 9.43 3 105 = 2.23 3 106
b-psychosine NM
a-GluCer 0.4711 / 9.37 3 104 = 5.02 3 106
C24:1 b-GluCer NM
a-glucopsychosine 0.1152 / 4.59 3 103 = 8.14 3 106
b-glucopsychosine NM
The structure of each ceramide is depicted in the right column. Measurements were carried out on a Biacore T200 at 25C. The same experiment was
repeated three times with similar results. NM indicates a nonmeasurable interaction.
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Endogenous a-Linked Ceramides Control NKT Cells(Kitteringham et al., 2009) to increase specificity and sensitivity
of detection in the immunoprecipitates. Transition profiles of all
glycosylceramides presented in Table 1 were determined and
used as standards (see Experimental Procedures). Using the
RBL-CD1d cell line as starting material, we demonstrated the
presence of a C24:1 glycosylceramide (mass of 809.67 Da) in
six independent experiments, whereas only traces of lyso-glyco-
sylceramide (mass of 462 Da) could be found in two experi-
ments. Similar compounds were isolated from the DC line
DC3.2. Both L363 and L317 antibodies isolated the samemolec-
ular species (Figure 4A).
This direct demonstration of a C24:1 monoglycosylceramide
species by MRM-MS did not allow us to eliminate that other
stimulatory species were also associated with CD1d. Indeed,
because we tested in vitro and in vivo, all a-glycosylceramides
with or without acyl chains (psychosines) had stimulatory activity
but much lower affinity for CD1d molecules and the L363 anti-body (Table 1); therefore, it is most likely that glucosylceramides
and lysoceramides would have been lost during the immunopur-
ification procedure. The stimulatory nature of the isolated glyco-
lipids could not be tested directly because of the very limited
quantities that we could isolate from 2 3 109 cells. Also, the
anomeric identity of the isolated compound could not be probed
directly by MS given that a- and b-anomers are isobaric species
or by NMRbecause quantities were so limiting. In conclusion, we
could isolate from cells molecular species corresponding to
C24:1 monoglycosylceramides by using two antibodies for
which we confirmed the specificity to CD1d-a-linked monogly-
cosylceramide complexes.
a-GalCer Is One of the Endogenous Ligands of NKTCells
On the basis of mass, we knew that the ligand we isolated
from RBL cells and DCs was a monoglycosylceramide with a
C24:1 fatty acid. To demonstrate the a-linkage, we producedImmunity 41, 543–554, October 16, 2014 ª2014 Elsevier Inc. 547
Figure 4. Endogenous NKT Ligands Recognized by L363 and L317 Antibodies Are Monoglycosylceramides and a-Linked
(A) Liquid chromatography-MRM-MS identified an 810 Da monoglycosylceramide in DC3.2 and RBL-CD1d cells. The lipid content of L363 and L317 antibody
immunoprecipitations from DC3.2 and RBL-CD1d cells (23 109 cells) was analyzed by MRM-MS. Ionization-transition profiles were defined for a-GalCer, C24:1
a-GalCer (shown in the figure), psychosines, and phytopsychosines. Untransfected RBL cells (5 3 109 cells) were used as a negative control.
(B) The a-linkage of the anomer was demonstrated by analysis of control antibody (ctl, normal rabbit IgG), anti-a-GalCer (aa, left), and anti-L363 (right) immu-
noprecipitations of C14-labeled RBL cells by TLC. C14UDP-galactose was used to label 53 107 RBL cells for 48 hr. In separate experiments, protein extracts were
immunoprecipitated with L363, whereas lipid extracts were immunoprecipitated with a purified anti-a-GalCer rabbit antibody. Immunoprecipitates were ex-
tracted with a 2:1 chloroform-methanol mixture and analyzed by high-performance TLC next to standards (std.) for a-GalCer and b-GalCer on plates that had
been pretreated with borate. Standards were cut and stained with cerium-ammonium-molybdate stain and charring. The experimental part of the TLCs was
fluorographed on Biomax MS films for 4–8 weeks.
Each experiment was repeated a minimum of three times. See also Figures S3 and S4.
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Endogenous a-Linked Ceramides Control NKT Cellsanti-a-GalCer antibodies in rabbits by repeated injections and
purification after ammonium sulfate precipitation on a streptavi-
din-biotinylated a-GalCer column. Specificity of the purified an-
tibodies was tested by SPR on liposomes retaining either a- or
b-GalCer (Figure S3). After developing a thin-layer chromatog-
raphy (TLC) protocol to separate a- and b-GalCer anomers
(see Experimental Procedures), we radiolabeled RBL-CD1d cells
with C14-UDP-galactose and used them for either immunopre-
cipitation with L363 antibodies or lipid extraction and immuno-
precipitation with the rabbit anti-a-GalCer antibodies. Each
immunoprecipitation was extracted with a 2:1 chloroform-meth-
anol mixture and analyzed by TLC next to a- and b-GalCer stan-
dards that we stained to locate the migration pattern of each
species. In both cases, the isolated monoglycosylceramides
migrated as a-anomers, confirming the previous results (Fig-
ure 4B). Three independent experiments yielded the same re-
sults and allowed us to estimate that the abundance of a-GalCer548 Immunity 41, 543–554, October 16, 2014 ª2014 Elsevier Inc.in RBL-CD1d cells was 0.02% of all galactosylceramides and
that 25% of these were associated with CD1d.
Degradation Controls the Amount of Natural
Endogenous NKT Ligands
As onewould predict for an innate-like lymphocyte, NKT cells are
activated rapidly and briefly so that stunning and anergy can be
avoided (Wilson et al., 2003). The time scale of the de novo syn-
thesis of glycosylceramides would not be the most appropriate
to address such a requirement for rapid stimulation (Hayes and
Jungalwala, 1976). An alternative mechanism would be to mobi-
lize a pre-existing pool or to limit the degradation of a compound
produced in very limited quantities and degraded efficiently.
Chemists and biochemists have ruled out the synthesis of
a-linked glycosylceramides by mammalian cells on the basis of
theoretical arguments favoring a SN2-like reaction over a SN1 re-
action in the ligation of UDP-a glucose or galactose to ceramide
Immunity
Endogenous a-Linked Ceramides Control NKT Cellsby glycosyltransferases (Lairson et al., 2008); this prediction has
been largely confirmed experimentally. However, the possibility
that small amounts of a-linked glycosylceramides could be pro-
duced by these enzymes or that under certain physiologic con-
ditions, such as the acidic environment of the lysosome, a-linked
species could be producedwith the help of anomeraseswill have
to be examined; we already know that the prolonged exposure of
b-GalCer and psychosine to pH 4.0 did not lead to any measur-
able conversion to a-anomers (Figure S4). The role that catabo-
lismmight play in the availability of endogenous NKT ligands was
suggested by the phenotype of NKT cells in a-galactosidase
(GLA) deficiency, also known as Fabry disease, in mice and hu-
mans (Darmoise et al., 2010; Pereira et al., 2013). Indeed, the
absence of GLA resulted in a profile of NKT cell hyperstimulation
that correlated with the presence of an increased amount of self-
ligands at the surface of selecting thymocytes and peripheral an-
tigen-presenting cells (Darmoise et al., 2010; Pereira et al., 2013).
We confirmed that compared to DCs from littermate control
animals, GLA-deficient DCs were hyperstimulatory toward
DN32.D3 T cells and that this activity was inhibited by L363 anti-
body (data not shown). GLA has been described as being exclu-
sively specific to terminal a-galactoses (Guce et al., 2010), and
in vitro digestion of a-GalCer confirmed that the proximal sugar
was indeed inaccessible when displayed by a ceramide. How-
ever, when we tested a-psychosine as a substrate, GLA was
capable of removing the a-linked galactose and eliminating the
stimulatory activity of this compound (Figures 5A and 5B). In vivo,
so far, only two lysosomal enzymes have been shown to remove
fatty acids from glycosylceramides: acid ceramidase (ASAH1;
Park and Schuchman, 2006), the most studied but whose defi-
ciency is embryonically lethal in mice (Eliyahu et al., 2007), and
N-acylamidehydrolase (ASHL), a poorly characterized enzyme
that is homologous to ASAH1 (Tsuboi et al., 2005). In the
absence of gene-deficient animal models, we used enzyme in-
hibitors to assess the role of ceramidases in the control of NKT
ligands. We used carmofur, a known commercial drug with
high specificity for ASAH1 (Realini et al., 2013), to demonstrate
that ASAH1 was upstream of GLA and necessary for its action;
indeed, the inhibition of ASAH1 induced an important increase
in stimulatory activity toward NKT cells, whereas the inhibition
of ASHL with a specific inhibitor (Li et al., 2012) resulted in a
very limited effect on the stimulatory activity of untreated or lipo-
polysaccharide (LPS)-treated DCs. Similarly, the inhibition of
a-GLA in DCs with 1-deoxygalactonojirimycin reproduced
in vitro the Fabry phenotype of increased stimulation, whereas
1-deoxygluconojirimycin, an inhibitor of acid a-glucosidase
(GAA; Ishii et al., 2009; Khanna et al., 2012; Wennekes et al.,
2009), did not influence stimulation (Figure 5C); however, in the
context of stimulation by a cytokine, such as tumor necrosis fac-
tor (TNF), which induced endogenous NKT ligands in DCs, both
inhibitors increased stimulation of NKT cells similarly (Figure S5).
The accumulation of a-GalCer during GLA and ASAH1 inhibition
was confirmed by indirect immunofluorescence using the puri-
fied rabbit anti-a-GalCer antibodies in RBL-CD1d cells treated
with the same inhibitors (Figure 5D). The specificity of staining
was confirmed by competing antibody binding with either free
b-GalCer (Figures 5Da–5Dd), which showed no inhibition, or
free a-GalCer (Figures 5De–5Dg), which completely blocked
staining. a-GalCer was found in small vesicles, some of whichcolocalized with CD1d-containing vesicles (Figures 5Db–5Dd).
Treatment of the RBL-CD1d cells for 24 hr with carmofur and
1-deoxygalactonojirimycin (Figures 5Dh–5Dk) increased the
number and size of the vesicles but never reached levels compa-
rable to what the addition of exogenous a-GalCer produced
(Figure 5Dk).
These results support a model in which the amount of endog-
enous a-glycosylceramides is directly controlled by catabolic
enzymes in a two-step mechanism: removal of the acyl chain
of a-ceramide and subsequent removal of the sugar by an
a-glycosidase. All together, these experiments have revealed
the existence of an important catabolic pathway that controls
the availability of natural NKT ligands and utilizes a two-step
enzymatic process to degrade a-glycosylceramides.
Ex Vivo and In Vivo Effect of CD1-a-GalCer Blockade
Using the same enzyme inhibitors, we examined the stimulatory
activity of thymocytes toward DN32.D3 T cells. In contrast to
the results of DCs, both glycosidase inhibitors modulated the
amount of cell-surface NKT ligands only marginally, and only
the inhibition of ASAH1 by carmofur had a substantial effect
(Figure S6). The possibility that both a-GluCer and a-GalCer
are produced in thymocytes is supported by an inhibition exper-
iment with L363 antibody. RBL-CD1d cells and thymocytes
were calibrated for stimulation toward DN32.D3 cells and
compared side by side against increasing concentration of
L363 antibody (Figure 6A). With increasing concentration of
antibody, stimulatory activity of both cell types diminished,
but the IC50 was 5 mg/ml for thymocytes and less than
0.325 mg/ml for RBL-CD1d cells. This difference could not
be explained by antibody target density given that RBL-CD1d
cells were more potent than thymocytes but could be explained
by differential affinity of the antibody on the two cell types
tested. Given the exclusive specificity of L363 for a-linked
monoglycosylceramides, we could reasonably hypothesize
that on thymocytes, in addition to a-GalCer, CD1d-a-GluCer
complexes were likely to be present and would require higher
concentration of antibody to be blocked, whereas RBL-CD1d
cells expressed mainly the higher-affinity CD1-a-GalCer com-
plexes. This information was critical for carrying out ex vivo ex-
periments because we argued that the low affinity of L363 anti-
body for thymic ligands would most likely result in the absence
of a detectable phenotype if concentrations of the antibody
were not sufficient. Therefore, we tested L363 at high concen-
tration on fetal thymic organ cultures and compared it to a nega-
tive control antibody (14.4.4 s) and a positive control anti-CD1
antibody (20H2). At day 18 of culture, day 14.5 thymi treated
with L363 antibody did not contain detectable NKT cells, as
measured with CD1d tetramers loaded with PBS-57 (Figure 6B).
Then, we performed the same experiment in vivo by injecting 8-
week-old female C57BL/6 mice with either 14.4.4 or L363 anti-
body over a 4-week period and examining thymic NKT
numbers. Compared to control thymi, thymi in the L363-treated
group were almost completely depleted of NKT cells (Figure 6C);
it is likely that the few remaining NKT cells represented the long-
lived thymic resident NKT cells that have been described (Ber-
zins et al., 2006). Finally, we used the anti-a-GalCer polyclonal
antibody to try to visualize a-GalCer-expressing cells in the
thymi of wild-type (WT) and GLA-deficient mice. In normalImmunity 41, 543–554, October 16, 2014 ª2014 Elsevier Inc. 549
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Figure 5. Catabolic Enzymes Control the Availability of a-Glycosylceramides
(A) High-performance TLC was used to separate glycosylceramides (left panel) and lyso-glycosylceramides (right panel) before and after digestion with
recombinant GLA. Lipids were visualized with a cerium ammonium molybdate stain. Abbreviations are as follows: Gal, GalCer; Glu, GluCer.
(B) Samples from a-GalCer (left) and a-psychosine (right) were tested for their stimulatory ability toward DN32.D3 NKT cells before (empty circles) and after
(filled circles) digestion with recombinant GLA. DC3.2 cells (20,000 cells/well) were used as antigen-presenting cells. A representative experiment out of three
independent experiments is shown.
(C) DC3.2 cells were differentiated with LPS, treated with inhibitors of a-glycosidases (GLAi and/or GAAi), 1-deoxygalactonojirimycin (0.5 mM), and 1-deoxy-
gluconojirimycin (2.0 mM) or with ceramidase inhibitors ASAHLi (20 mM; Li et al., 2012) or ASAH1i (carmofur, 1.0 mM) for 24 hr, and used to stimulate DN32.D3 NKT
cells. A control (empty circles) is included in each panel for comparison with inhibitors (filled circles).
(D) Confocal microscopy of a-GalCer in RBL-CD1d cells by indirect immunofluorescence. Flattened Z series are presented. Anti-a-GalCer antibody is in red,
whereas anti-CD1d antibody is in green. Control stains include normal rabbit Ig, 14.4.4 antibody, and secondary antibodies (a and h). In (b), (c), and (d), cells were
incubated in the presence of 10 mg/ml b-GalCer at the time of staining, whereas in (e), (f), and (g), cells were incubated in the presence of 10 mg/ml a-GalCer. An
overlay of each group is presented in (d) and (g). In (h)–(k), cells were either untreated (i) or treated with 0.5 mM 1-deoxygalactonojirimycin and 1.0 mM carmofur (j)
or 2.0 mg/ml a-GalCer (k) for 24 hr in 0.05% serum-free media containing BSA. All cells were permeabilized with 0.05% saponin. All scale bars represent 20 mm.
See also Figures S4–S6.
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Endogenous a-Linked Ceramides Control NKT Cellsthymi, few islands (five to ten cells) were labeled in the cortex
and costained with anti-CD3 antibodies, whereas GLA-deficient
thymi were intensely stained throughout the cortex and medulla,
indicating a large increase in the quantities of a-GalCer (Fig-
ure 6D). Thus, we confirmed ex and in vivo that thymic selection
of NKT cells could be inhibited by L363 antibody blocking of
CD1d-a-monoglycosylceramide complexes. In addition, it is
likely that both a-GalCer and a-GluCer are selecting ligands of
NKT cells.550 Immunity 41, 543–554, October 16, 2014 ª2014 Elsevier Inc.DISCUSSION
The biochemical analysis of lipids has been limited by the lack of
sensitivity of available analytical techniques. We have ad-
dressed these limitations by combining the exquisite sensitivity
of T cells in biological assays with the specificity of immunoglob-
ulins, the ability to immunopurify lipids with antibodies, the ste-
reospecificity of catabolic enzymes, and new techniques such
as MRM-MS to identify and characterize the natural
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Figure 6. Thymocytes Present More Than One a-Glycosylceramide
(A) Titration of DN32.D3-cell-stimulation inhibition by L363 antibody with the use of thymocytes (left panel) or RBL-CD1d cells as antigen-presenting cells. Seven
two-fold dilutions were tested from a 20 mg/ml stock. In the lower panel, the percentage of inhibition was plotted as the percentage of maximal response (100%)
for RBL-CD1d cells (black symbols) and thymocytes (empty circles).
(B) Day 14.5 thymic lobeswere cultured for 18 days in the presence of 40–60 mg of antibody. 14.4.4 s was the negative control antibody, and 20H2was the positive
control antibody. In this particular experiment, percentages of CD1-PBS57-positive cells were 0.27%, 8.02%, 1.14%, and 0.27% for adult thymus, 14.4.4 s, L363,
and 20H2, respectively. Similar results were obtained on four other thymic lobes. The experiment was repeated three times. FTOC, fetal thymic organ culture.
(C) Mice were treated with either 14.4.4 control or L363 antibody for 4 weeks and examined for thymic NKT cell numbers. The lowering of NKT cell numbers in the
L363-treated group was significant (p = 0.0147).
(D) Staining of WT and Gla/ thymic sections with purified anti-a-GalCer rabbit antibody (green) and anti-CD3 antibody (red). Control staining was with sec-
ondary antibodies only. Sections (a), (b), and (c) were magnified 203. Section (d), from a WT thymus, was magnified 403. Similar images were obtained in three
independent experiments on WT and Gla/ thymi. Scale bars represent 100 mm in (a)–(c) and 50 mm in (d).
See also Figure S6.
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Endogenous a-Linked Ceramides Control NKT Cellsendogenous ligands of NKT cells. This approach identified
several types of a-glycosylceramides as the main endogenous
ligands of NKT cells in the thymus and the periphery if we
consider in a reductionist approach that DCs are the most rele-
vant cell type for NKT functions in the periphery (Arora et al.,
2014). The current discovery sheds light on a number of unex-
plained observations in the field of NKT biology. First, the likely
presence of both a-GluCer and a-GalCer in the thymus explains
why the removal of a single pathway, such as performed in the
acid-galactosylceramidase-deficient animal, did not eliminate
NKT cells (Bendelac et al., 2007; Stanic et al., 2003). Indeed,
the reciprocal compensation of glucosylceramide versus galac-
tosylceramide species has been well documented in various
lysosomal-storage diseases (Coetzee et al., 1996; Jennemannet al., 2005; Tadano-Aritomi et al., 2000). Second, the presence
of the two species of a-glycosylceramide in the thymus would
explain the differential reactivity of thymic NKT cells to a-GluCer
and a-GalCer CD1d tetramers and their preferential reactivity to
Vb7 and Vb8 NKT cells, respectively (Wun et al., 2011). Third, our
results explain the phenotype of the Fabry mouse that was
recently reported (Darmoise et al., 2010) and support the idea
that catabolism is an important factor controlling the amount
of NKT agonists. In the Fabry mouse, even though the lysosome
is dysfunctional, NKT cells are hyperstimulated in the periphery
and exhibit signs of permanent activation. The idea that degra-
dation is an important factor controlling the amount of NKT
cell ligands is also supported by proteomics studies of the se-
cretome of monocytes; these demonstrated that all the essentialImmunity 41, 543–554, October 16, 2014 ª2014 Elsevier Inc. 551
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ASAH1) are rapidly produced upon activation and allow a fast
control of NKT cell activation in the context of inflammation
and infection (Meissner et al., 2013). It is also important to
note that a two-step degradation process is required for the
complete removal of stimulatory activity given that a-glycosi-
dase, as shown for GLA, only cleaves the sugar from lysocera-
mides. In this respect, we will have to evaluate the respective
roles that ASAH1 and ASHL play in the process of producing
a-psychosines, a task that will be made difficult by the fact
that the ASAH1 deficiency is embryonically lethal in mice (Eli-
yahu et al., 2007). The fourth conclusion of our study is that
the dual nature of the endogenous ligands of NKT cells, as
mentioned for thymic NKT cells, most likely is the basis for the
tissue specificity of NKT cell subpopulations (Park et al.,
1998). It is reasonable to hypothesize that the balance between
glucosyl and galactosyl species, as seen between thymocytes
and DCs, is a general mechanism that favors the local expansion
of NKT cells tuned for the recognition of one or the other ligand.
The possibility that both a-GluCer and a-galactosylceramides
could be modified at positions 3 and 6 by either a sulfate or an
acetyl group will also have to be explored, given that we know
that the synthetic forms of these modified a-glycosylceramides
are powerful agonists of NKT cells in vitro. The possibility that
a-lyso-glycosylceramide and a-glycosylceramide recognition
is finely tuned by the nature of the Vb chain should also be exam-
ined. Finally, follow-up studies will have to address the mecha-
nisms leading to the production of a-anomers of glycolipids. It
could be as simple as the noninversion of the sugar by GCS or
CGT during synthesis or the synthetic function of ASAH1 (Okino
et al., 2003) and glycosidases (Yamashita et al., 2005) after alter-
ation of substrate availability. More complex situations requiring
specific anomerases will also have to be considered, given that
none is exclusive.
In conclusion, the immune system and immune probes have
allowed us to reveal the existence of a metabolic and degrada-
tive pathway that produces a-linked glycolipids. This pathway
is most likely critical for the generation and control of NKT cell
activation in the thymus and the periphery. Given the close iden-
tity of the murine and human NKT cell systems, it is most likely
that the same a-glycolipids will be identified in man. The under-
standing of the transcriptional control of this pathway should
allow new approaches in the utilization of NKT cells in immuno-
therapy. Finally, potential nonimmunological functions of these
new glycolipids will have to be examined.
EXPERIMENTAL PROCEDURES
Cells, Cell Lines, and DC Maturation
DN32.D3 and TBA7 cells have been described extensively in other publica-
tions and are commonly used as representatives of type 1 semi-invariant
Va14 NKT cells and type 2 non-Va14 NKT cells, respectively. DC3.2 cells
are a DC line expressing CD1d and are susceptible to differentiation
induced by TLR ligands and cytokines, such as LPS and TNF (Shen
et al., 1997).
Polyclonal primary NKT cell lines were established by fluorescence-acti-
vated cell sorting of fresh NKT cells from thymi with CD1d tetramers for stain-
ing. After sorting, cells were expanded in vitro by stimulation with anti-TCRb
and -CD28 antibodies for 2 days and the subsequent addition of IL-7 for
5 days. Bone-marrow-derived DCs were cultured in the presence of GM-
CSF for 7 days.552 Immunity 41, 543–554, October 16, 2014 ª2014 Elsevier Inc.Mice were purchased from the Jackson Laboratory and kept in the care
of the Scripps Research Institute Immunology Vivarium according to the Insti-
tutional Animal Care and Use Committee guidelines.
Antibodies and Antibody Production and Purification
L363 (IgG2a) and L317 (IgG1) antibodies were a generous gift from Steve Por-
celli. In most experiments, the anti-MHC class II antibodies MKD6 (anti-I-Ad,
IgG2a) and 14.4.4 s (anti-I-Ek, IgG2a) were used as controls. Rabbit polyclonal
anti-a-Galcer antibodies were produced over a 6-month period by repeated
subcutaneous immunizations of New Zealand rabbits with 20 mg a-GalCer
in incomplete Freund’s adjuvant. See also Supplemental Experimental
Procedures.
Radiolabeling of RBL Cells
RBL-CD1d cells at 50% confluency were labeled with 10 mM C14-UDP galac-
tose per flask. After washing with PBS, protein extraction was carried out for
L363 immunoprecipitation, whereas lipids were extracted for immunoprecipi-
tation with anti-a-GalCer antibodies. See also Supplemental Experimental
Procedures.
T Cell Activation Assay
Antigen-presentation assays were carried out with 53 103 to 203 103 DC3.2
cells or 1 3 105 splenocytes and 4 3 104 T cells per well in 96-well tissue-
culture plates in triplicates. Cell-culture supernatants were collected 24 hr later
for determination of IL-2 concentrations with an IL-2-dependent NK cell line
reporter system.
Flow Cytometry
NKT cells were quantified with CD1d tetramers empty or loaded with PBS-57.
Samples were acquired on a MACSQuant analyzer with MACSQuantify soft-
ware (both Miltenyi Biotec) and analyzed with FlowJo software (Tree Star).
See also Supplemental Experimental Procedures.
Fetal Thymic Organ Culture
Embryonic day 14.5 fetal thymic lobes were harvested from timed pregnant
C57BL/6J mice and cultured on nitrocellulose filters (Whatman) placed on
a sponge (Gelfoam size 4; Upjohn Pharmacia). Lobes were cultured for
18 days in Dulbecco’s modified Eagle’s medium before being analyzed. See
also Supplemental Experimental Procedures.
In Vivo Treatment with Antibodies
Eight-week-old C57BL/6 mice were injected intraperiteonally every 5 days
with 1 mg of either 14.4.4 or L363 antibody for a period of 4 weeks. Thymi
were harvested and processed individually at week 5.
TLC and TLC Blot
TLC analysis was carried out with aluminum back plates (EMD Bioscience).
Running solutions and visualization are detailed in the Supplemental Experi-
mental Procedures.
Liquid Chromatography and MS
An Agilent 1200 UPLC system was coupled to a 6490 Triple Quadrupole mass
spectrometer for use in C24:1 monoglycosylceramide determination using
MRM for enhanced sensitivity and selectivity. See also Supplemental Experi-
mental Procedures.
Histology and Indirect Immunofluorescence
Tissues were embedded in optimum cutting temperature compound and flash
frozen (Tissue-Tek) before being sectioned and processed. For immunofluo-
rescence on cells, cells were cultured for 24 hr in serum-free media containing
0.05% BSA on coated coverslips. Visualization was by confocal microscopy.
See also Supplemental Experimental Procedures.
SPR
A Biacore T200 instrument (GE Healthcare) was used for SPR measurements.
Measurements were performed according to single-cycle protocols for avoid-
ing the repeated use of regeneration buffer on the immobilized ligands. See
also Supplemental Experimental Procedures.
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Procedures and can be found with this article online at http://dx.doi.org/10.
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